Scientists hunt for biomarkers to unlock rare eye disease treatments

NCT ID NCT07063719

Recruiting now Knowledge-focused Sponsor: Institut National de la Santé Et de la Recherche Médicale, France Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 08, 2026 · Updated 3 times

Summary

This study aims to find biological markers (biomarkers) in blood, tears, and eye cells from 110 adults with seven rare eye diseases. Researchers will compare these markers between patients and healthy controls to see if they differ and if they relate to disease symptoms. The goal is to better understand these diseases and support future drug development.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this study could identify key biological markers that help design and test new treatments for rare eye diseases.
What could go wrong: This is an observational study, not a treatment trial. It is early-stage research, and the findings may not directly lead to new therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANIRIDIA-ASSOCIATED KERATOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

aniridia chronic graft versus host disease corneal neovascularization EEC syndrome graft versus host disease limbal stem cell deficiency neurotrophic keratopathy ocular cicatricial pemphigoid Rare Diseases

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OPHTHALMOLOGY RARE DISEASES

Contacts and locations

Locations

Hôpital Universitaire Cochin, APHP
RECRUITING

Paris, France
Hôpital Universitaire Necker Enfants malades, APHP
NOT_YET_RECRUITING

Paris, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.